GoodRx (GDRX) 10-Q2024 Q3 Quarterly report

Filed: 7 Nov 24, 2:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abuse, Aid, Andr, asset, Benjamin, Birotte, Bushansky, Caetano, caption, casualty, Colby, commonly, Comprehensive, Concurrent, declaratory, detailed, disaggregated, Disaggregation, dollar, driver, duty, entity, extension, fiduciary, floor, flow, footprint, heightened, illegal, immaterially, indemnification, insider, inventory, Joseph, Jr, Kalmanson, levy, mandatory, Marshal, migrate, mismanagement, nil, owed, phase, purportedly, rapid, rationalizing, refinance, refinancing, repaid, repayment, restitution, retrospectively, Rite, roll, routed, Sharon, Solomon, Stephen, store, Subtopic, traffic, transient, turn, unamortized, voluntary, waste, writ

Removed: equal, sequentially

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated GDRX transcripts

GDRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of GoodRx Holdings, Inc. (the “Company”) for the period ended

September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify,

pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my

knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;

and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of

operations of the Company.


Date: November 7, 2024	By:	/s/ Karsten Voermann
		Karsten Voermann
		Chief Financial Officer (Principal Financial Officer)